The UK Competition and Markets Authority on Tuesday said it has decided not to accept undertakings given by Celesio AG in respect of its proposed acquisition of J Sainsbury PLC’s pharmacy business.
The acquisition will therefore be referred to a Phase 2 investigation.
Sainsbury’s agreed to sell its pharmacy business to Celesio for GBP125 million in July. Under the deal, Lloyds Pharmacy, which is owned by Celesio, would buy 281 pharmacies in total, including 277 in-store locations and four located in hospitals, to be re-branded under Lloyds Pharmacy.
Earlier this month, the CMA had ruled that the acquisition may result in a “substantial” lessening of competition in the UK.
Full content: The Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Reserve Greenlights Capital One’s $35.3 Billion Acquisition of Discover
Apr 18, 2025 by
CPI
Google to Appeal Partial Ruling in DOJ Antitrust Case
Apr 18, 2025 by
CPI
Indian Ad Agencies Warned Against WhatsApp Discussions After Antitrust Raids
Apr 17, 2025 by
CPI
US Court Ruling Against Google Spurs Fresh Antitrust Tensions in Europe
Apr 17, 2025 by
CPI
AstraZeneca Accused of Stifling Biosimilar Competition for Rare Disease Drug
Apr 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Airline Industry
Apr 10, 2025 by
CPI
Boosting Competition in International Aviation
Apr 10, 2025 by
Jeffrey N. Shane
Reshaping Competition Policy for the U.S. Airline Industry
Apr 10, 2025 by
Diana L. Moss
Algorithmic Collusion in the Skies: The Role of AI in Shaping Airline Competition
Apr 10, 2025 by
Qi Ge, Myongjin Kim & Nicholas Rupp
Competition in U.S. Airline Markets: Major Developments and Economic Insights
Apr 10, 2025 by
Germán Bet